For long-term prevention in C1-INH deficiency, kallikrein inhibition (e.g., Lanadelumab; oral Berotralstat) and regular pd-C1-INH reduce attack rates in hereditary disease; in AAE, prophylaxis is individualized and often secondary to controlling the hematologic driver [8,17]. Here, KLK4 is linked to acquired angioedema.